Publikationen in Zusammenarbeit mit Forschern von Hacettepe University (47)

2024

  1. Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom

    Journal of medical economics, Vol. 27, Núm. 1, pp. 109-125

  2. Impact of HLA-B51 on Uveitis and Retinal Vasculitis: Data from the AIDA International Network Registries on Ocular Inflammatory Disorders

    Ocular Immunology and Inflammation

  3. Recovery course of persistent posterior subretinal fluid after successful repair of rhegmatogenous retinal detachment

    European Journal of Ophthalmology, Vol. 34, Núm. 4, pp. 1217-1227

  4. Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson’s disease study

    Brain, Vol. 147, Núm. 8, pp. 2652-2667

2023

  1. A patient-driven registry on Behçet’s disease: the AIDA for patients pilot project

    Frontiers in Medicine, Vol. 10

  2. Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis

    JAMA Neurology, Vol. 80, Núm. 7, pp. 702-713

  3. Comparative effectiveness in multiple sclerosis: A methodological comparison

    Multiple Sclerosis Journal, Vol. 29, Núm. 3, pp. 326-332

  4. Disability accrual in primary and secondary progressive multiple sclerosis

    Journal of Neurology, Neurosurgery and Psychiatry, Vol. 94, Núm. 9, pp. 707-717

  5. Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis

    Multiple sclerosis (Houndmills, Basingstoke, England), Vol. 29, Núm. 7, pp. 875-883

  6. Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial

    Journal of neurology, neurosurgery, and psychiatry, Vol. 94, Núm. 12, pp. 1004-1011

  7. Respective roles of non-pharmaceutical interventions in bronchiolitis outbreaks: an interrupted time-series analysis based on a multinational surveillance system

    The European respiratory journal, Vol. 61, Núm. 2

  8. Rituximab-associated hypogammaglobulinemia in children with idiopathic nephrotic syndrome: results of an ESPN survey

    Pediatric Nephrology, Vol. 38, Núm. 9, pp. 3035-3042

  9. The risk of secondary progressive multiple sclerosis is geographically determined but modifiable

    Brain : a journal of neurology, Vol. 146, Núm. 11, pp. 4633-4644

  10. Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis

    European Journal of Neurology, Vol. 30, Núm. 4, pp. 1014-1024

2022

  1. Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis: An International Registry Study

    Neurology, Vol. 98, Núm. 24, pp. E2401-E2412

  2. FXR1 -related congenital myopathy: expansion of the clinical and genetic spectrum

    Journal of Medical Genetics, Vol. 59, Núm. 11, pp. 1069-1074

  3. It is time to define an organizational model for the prevention and management of infections along the surgical pathway: a worldwide cross-sectional survey

    World Journal of Emergency Surgery, Vol. 17, Núm. 1

  4. Parathyroid hormone and phosphate homeostasis in patients with Bartter and Gitelman syndrome: an international cross-sectional study

    Nephrology Dialysis Transplantation, Vol. 37, Núm. 12, pp. 2474-2486

  5. Presentations of children to emergency departments across Europe and the COVID-19 pandemic: A multinational observational study

    PLoS medicine, Vol. 19, Núm. 8, pp. e1003974

2021

  1. Co-infections and superinfections complicating COVID-19 in cancer patients: A multicentre, international study

    Journal of Infection, Vol. 83, Núm. 3, pp. 306-313